Tenax Therapeutics
TENX
Tenax Therapeutics (TENX) analyst forecast and price target
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Guggenheim | Downgraded | Buy → Neutral | — | Aug 31, 2026 |
| Evercore ISI Group | Downgraded | Outperform → In-Line | $5.00 from $39.00 | Aug 11, 2026 |
| Guggenheim | Maintained | Buy | $4.00 from $40.00 | Aug 11, 2026 |
| Canaccord Genuity | Maintained | Buy | $4.00 from $35.00 | Aug 11, 2026 |
| Chardan Capital | Downgraded | Buy → Neutral | $5.00 from $27.00 | Aug 11, 2026 |
| William Blair | Downgraded | Outperform → Market Perform | — | Aug 10, 2026 |
| Chardan Capital | Maintained | Buy | $27.00 | Jul 31, 2026 |
| Cantor Fitzgerald | Maintained | Overweight | $35.00 | Jul 29, 2026 |
| Canaccord Genuity | Initiated Coverage | Buy | $35.00 | Jul 28, 2026 |
| Evercore ISI Group | Initiated Coverage | Outperform | $39.00 | Jul 22, 2026 |
| Chardan Capital | Maintained | Buy | $27.00 | Jul 2, 2026 |
| Cantor Fitzgerald | Maintained | Overweight | $35.00 | Jun 24, 2026 |
| Guggenheim | Maintained | Buy | $40.00 from $34.00 | Jun 22, 2026 |
| Chardan Capital | Initiated Coverage | Buy | $27.00 | Jun 22, 2026 |
| Piper Sandler | Maintained | Overweight | $50.00 from $20.00 | Jun 12, 2026 |
| Cantor Fitzgerald | Initiated Coverage | Overweight | $35.00 | Mar 17, 2026 |
| Guggenheim | Maintained | Buy | $34.00 from $25.00 | Mar 16, 2026 |
| Guggenheim | Maintained | Buy | $25.00 from $14.00 | Dec 17, 2025 |
| Piper Sandler | Initiated Coverage | Overweight | $20.00 | Sep 8, 2025 |
| Guggenheim | Maintained | Buy | $14.00 from $15.00 | Aug 14, 2025 |
Frequently asked questions
What is the latest analyst rating on TENX?
On Aug 31, 2026, Guggenheim downgraded Tenax Therapeutics to Neutral.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.